Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,946
  • Shares Outstanding, K 17,553
  • Annual Sales, $ 460 K
  • Annual Income, $ -5,800 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.99
  • Price/Sales 66.58
  • Price/Cash Flow N/A
  • Price/Book 3.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/25
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.17
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +58.26%
on 03/04/25
1.8955 -3.98%
on 03/24/25
+0.3400 (+22.97%)
since 02/25/25
3-Month
1.1500 +58.26%
on 03/04/25
2.4300 -25.10%
on 01/06/25
-0.3900 (-17.65%)
since 12/24/24
52-Week
1.1500 +58.26%
on 03/04/25
4.4400 -59.01%
on 06/03/24
-2.1300 (-53.92%)
since 03/25/24

Most Recent Stories

More News
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Additions broaden DehydraTECH patent suite for Epilepsy

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria Releases Annual Letter from the CEO

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide...

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®

LEXXW : 0.3325 (-14.74%)
LEXX : 1.8200 (+3.41%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 2.0150
2nd Resistance Point 1.9320
1st Resistance Point 1.8760
Last Price 1.8200
1st Support Level 1.7370
2nd Support Level 1.6540
3rd Support Level 1.5980

See More

52-Week High 4.4400
Fibonacci 61.8% 3.1832
Fibonacci 50% 2.7950
Fibonacci 38.2% 2.4068
Last Price 1.8200
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar